Ư¹ß¼º Ç÷¼ÒÆÇ °¨¼Ò¼º ÀÚ¹ÝÁõ Ä¡·áÁ¦ ½ÃÀå - Á¦Ç° À¯Çü, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ªº°(ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, MEA) : ¼¼°è »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2023-2030³â)
Idiopathic Thrombocytopenic Purpura Therapeutics Market by Product Type, End-Users, & Geography (North America, Europe, Asia Pacific, Latin America, & MEA): Global Industry Analysis, Size, Share, Growth, Trends, & Forecast, 2023-2030
»óǰÄÚµå : 1450765
¸®¼­Ä¡»ç : Persistence Market Research
¹ßÇàÀÏ : 2024³â 01¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 130 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,995 £Ü 7,227,000
Unprintable PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ º¹»ç, ÀμⰡ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 7,295 £Ü 10,555,000
PDF & Excel (Multi User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste¿Í ÀμⰡ °¡´ÉÇÕ´Ï´Ù.
US $ 8,495 £Ü 12,291,000
PDF & Excel (Corporate User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste¿Í ÀμⰡ °¡´ÉÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

Persistence Market Research´Â Ư¹ß¼º Ç÷¼ÒÆÇ °¨¼Ò¼º ÀÚ¹ÝÁõ Ä¡·áÁ¦ ½ÃÀå¿¡ ´ëÇÑ Ã¶ÀúÇÑ ºÐ¼®°ú ¼¼°è Àü¸ÁÀ» ÀÚ¼¼È÷ ¼³¸íÇÏ´Â Á¾ÇÕÀûÀÎ º¸°í¼­¸¦ Á¦°øÇÕ´Ï´Ù. ÀÌ »ó¼¼ÇÑ °£Ç๰Àº ½ÃÀå ¿ªÇÐ, µ¿Çâ, ±âȸ ¹× °úÁ¦¿¡ ´ëÇÑ ±ÍÁßÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÏ°í ±× ±¸Á¶¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ °³¿ä¸¦ Á¦°øÇÕ´Ï´Ù. ÀÌ ¿¬±¸´Â µ¶ÀÚÀûÀÎ µ¥ÀÌÅÍ¿Í Åë°è¸¦ ¹ÙÅÁÀ¸·Î 2023³âºÎÅÍ 2030³â±îÁö Ư¹ß¼º Ç÷¼ÒÆÇ °¨¼Ò¼º ÀÚ¹ÝÁõ Ä¡·áÁ¦ ½ÃÀåÀÇ ¿¹»ó ¼ºÀå ±ËÀûÀ» ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù.

Ư¹ß¼º Ç÷¼ÒÆÇ °¨¼Ò¼º ÀÚ¹ÝÁõ Ä¡·áÁ¦ ½ÃÀåÀº ¿¬Æò±Õ 5.0%·Î ²ÙÁØÈ÷ ¼ºÀåÇÏ¿© 2023³â 6¾ï 5,000¸¸ ´Þ·¯¿¡¼­ 2030³â ¸» 9¾ï 2,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÁÖ¿ä ÀλçÀÌÆ®

Ư¹ß¼º Ç÷¼ÒÆÇ °¨¼Ò¼º ÀÚ¹ÝÁõ Ä¡·áÁ¦ ½ÃÀå - Á¶»ç ¹üÀ§

Ư¹ß¼º Ç÷¼ÒÆÇ °¨¼Ò¼º ÀÚ¹ÝÁõ(ITP)Àº Ç÷¼ÒÆÇ ¼ö °¨¼Ò¸¦ Ư¡À¸·Î ÇÏ´Â Èñ±ÍÇÑ ÀÚ°¡¸é¿ªÁúȯÀ¸·Î ÃâÇ÷ À§ÇèÀ» Áõ°¡½ÃŰ´Â ÁúȯÀÔ´Ï´Ù. ITP Ä¡·áÁ¦ ¼¼°è ½ÃÀå ¼ºÀåÀº Çõ½ÅÀûÀÎ Ä¡·á ¿É¼Ç, ÀÇÇÐ ¿¬±¸ ¹× ±â¼ú ¹ßÀü, ITP ȯÀÚÀÇ Àü ¼¼°è À¯º´·ü Áõ°¡¿¡ µû¸¥ Çõ½ÅÀû Ä¡·á ¿É¼Ç, ITP¿¡ ´ëÇÑ Àνİú Áø´Ü, ±ÔÁ¦ °­È­·Î ÀÎÇØ ¹ß»ýÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÎÁöµµ¿Í Áø´ÜÀ²ÀÇ Áõ°¡, ±ÔÁ¦ ±â°ü, Á¦¾à»ç, ÀÇ·á ¼­ºñ½º Á¦°øÀÚ °£ÀÇ Çù·ÂÀº ½ÃÀå È®´ë¸¦ ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÇöÀç ÁøÇà ÁßÀÎ Ä¡·á¹ý °³¹ß ¹× °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ³ë·Âµµ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ

Ư¹ß¼º Ç÷¼ÒÆÇ °¨¼Ò¼º ÀÚ¹ÝÁõ(ITP) Ä¡·áÁ¦ ¼¼°è ½ÃÀåÀº ÀÌ ÁúȯÀÇ º¹À⼺À» ÀÌÇØÇϰí Ç¥ÀûÈ­µÈ Ä¡·á¹ýÀ» °³¹ßÇÏ´Â µ¥ ÁßÁ¡À» µÐ ¿¬±¸ °³¹ßÀÌ È°¹ßÈ÷ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. ÀÌÇØ°ü°èÀÚ °£ÀÇ Çù·Â°ú ÷´Ü ±â¼úÀÌ ¹ßÀüÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ¿©ÀüÈ÷ ³·Àº ÀÎÁöµµ¿Í °ú¼Ò Áø´ÜÀº Àû½Ã¿¡ Áø´Ü°ú Ä¡·á, ±×¸®°í È®½ÇÇÑ ÀÓ»ó½ÃÇè ¼öÇàÀ» ¹æÇØÇÏ´Â Àå¾Ö¹°·Î ³²¾ÆÀÖ½À´Ï´Ù.

½ÃÀå ¾ïÁ¦¿äÀÎ

Ư¹ß¼º Ç÷¼ÒÆÇ °¨¼Ò¼º ÀÚ¹ÝÁõ(ITP) Ä¡·áÁ¦ÀÇ ³ôÀº ºñ¿ëÀ¸·Î ÀÎÇÑ °æÁ¦Àû ºÎ´ãÀº ¼¼°è ½ÃÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â Áß¿äÇÑ ¿äÀÎÀÔ´Ï´Ù. È¿´É°ú ºÎÀÛ¿ë °¨¼Ò¿¡µµ ºÒ±¸Çϰí Ç¥ÀûÄ¡·áÁ¦ ¹× ¸é¿ªÁ¶ÀýÁ¦´Â ³ôÀº ºñ¿ëÀ¸·Î ÀÎÇØ º¸±Þ¿¡ ¾î·Á¿òÀ» °Þ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °æÁ¦Àû ºÎ´ãÀº ÀÇ·á ½Ã½ºÅÛ, º¸Çè»ç ¹× ȯÀÚ¿¡°Ô ¿µÇâÀ» ¹ÌÄ¡¸ç, ITPÀÇ Àå±âÀûÀÎ °ü¸® ¿ä±¸·Î ÀÎÇØ ´õ¿í ½É°¢ÇØÁö°í ÀÖ½À´Ï´Ù. ¾à¹° ºñ¿ë»Ó¸¸ ¾Æ´Ï¶ó Áö¼ÓÀûÀÎ ¸ð´ÏÅ͸µ, ÁöÁö ¿ä¹ý, ÃâÇ÷ ¿¡ÇǼҵ忡 ´ëÇÑ ÀáÀçÀû °³ÀÔ µîÀÌ °æÁ¦Àû ºÎ´ãÀ» °¡Áß½Ã۰í ÀÖ½À´Ï´Ù.

½ÃÀå ±âȸ

Ư¹ß¼º Ç÷¼ÒÆÇ °¨¼Ò¼º ÀÚ¹ÝÁõ(ITP) Ä¡·áÁ¦ ½ÃÀåÀº ¸é¿ª Á¶ÀýÁ¦ ¹× Ç¥Àû Ä¡·áÁ¦ÀÇ »ç¿ë È®´ë°¡ ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ä¡·á¹ýÀº Ç÷¼ÒÆÇ ÆÄ±«¸¦ À¯¹ßÇϴ ƯÁ¤ ¸é¿ª°è ¼ººÐÀ» Á¶ÀýÇÔÀ¸·Î½á º¸´Ù Á¤È®Çϰí È¿°úÀûÀÎ Á¢±Ù¹ýÀ» Á¦°øÇϸç, B¼¼Æ÷ ¹× ºñÀå Æ¼·Î½Å Ű³ª¾ÆÁ¦¸¦ Ç¥ÀûÀ¸·Î ÇÏ´Â ´ÜŬ·ÐÇ×ü¿Í °°Àº Çõ½ÅÀûÀÎ ¾à¹°Àº Ä¡·á ÆÐ·¯´ÙÀÓÀ» À籸¼ºÇϰí ÀÓ»ó½ÃÇè¿¡¼­ À¯¸ÁÇÑ °á°ú¸¦ º¸À̰í ÀÖ½À´Ï´Ù. Æ®·Òº¸Æ÷ÀÌ¿¡Æ¾ ¼ö¿ëü ÀÛ¿ëÁ¦¿Í °°Àº »õ·Î¿î Ç¥Àû¿¡ ´ëÇÑ ¿¬±¸ °³¹ßÀÌ ÁøÇà ÁßÀ̾ »õ·Î¿î Ä¡·á ¿É¼Ç °³¹ß¿¡ ´ëÇÑ ³«°ü·ÐÀÌ ´õ¿í Ä¿Áö°í ÀÖ½À´Ï´Ù.

º» º¸°í¼­¿¡¼­ ´Ù·ç´Â ÁÖ¿ä Áú¹®

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå °³¿ä

Á¦3Àå ¼¼°èÀÇ Æ¯¹ß¼º Ç÷¼ÒÆÇ °¨¼Ò¼º ÀÚ¹ÝÁõ Ä¡·áÁ¦ ½ÃÀå Àü¸Á : ½ÇÀû(2018-2022³â)°ú ¿¹Ãø(2023-2030³â)

Á¦4Àå ¼¼°èÀÇ Æ¯¹ß¼º Ç÷¼ÒÆÇ °¨¼Ò¼º ÀÚ¹ÝÁõ Ä¡·áÁ¦ ½ÃÀå Àü¸Á : Áö¿ª

Á¦5Àå ºÏ¹ÌÀÇ Æ¯¹ß¼º Ç÷¼ÒÆÇ °¨¼Ò¼º ÀÚ¹ÝÁõ Ä¡·áÁ¦ ½ÃÀå Àü¸Á : ½ÇÀû(2018-2022³â)°ú ¿¹Ãø(2023-2030³â)

Á¦6Àå À¯·´ÀÇ Æ¯¹ß¼º Ç÷¼ÒÆÇ °¨¼Ò¼º ÀÚ¹ÝÁõ Ä¡·áÁ¦ ½ÃÀå Àü¸Á : ½ÇÀû(2018-2022³â)°ú ¿¹Ãø(2023-2030³â)

Á¦7Àå µ¿¾Æ½Ã¾ÆÀÇ Æ¯¹ß¼º Ç÷¼ÒÆÇ °¨¼Ò¼º ÀÚ¹ÝÁõ Ä¡·áÁ¦ ½ÃÀå Àü¸Á : ½ÇÀû(2018-2022³â)°ú ¿¹Ãø(2023-2030³â)

Á¦8Àå ³²¾Æ½Ã¾Æ ¹× ¿À¼¼¾Æ´Ï¾ÆÀÇ Æ¯¹ß¼º Ç÷¼ÒÆÇ °¨¼Ò¼º ÀÚ¹ÝÁõ Ä¡·áÁ¦ ½ÃÀå Àü¸Á : ½ÇÀû(2018-2022³â)°ú ¿¹Ãø(2023-2030³â)

Á¦9Àå ¶óÆ¾¾Æ¸Þ¸®Ä«ÀÇ Æ¯¹ß¼º Ç÷¼ÒÆÇ °¨¼Ò¼º ÀÚ¹ÝÁõ Ä¡·áÁ¦ ½ÃÀå Àü¸Á : ½ÇÀû(2018-2022³â)°ú ¿¹Ãø(2023-2030³â)

Á¦10Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Æ¯¹ß¼º Ç÷¼ÒÆÇ °¨¼Ò¼º ÀÚ¹ÝÁõ Ä¡·áÁ¦ ½ÃÀå Àü¸Á : ½ÇÀû(2018-2022³â)°ú ¿¹Ãø(2023-2030³â)

Á¦11Àå °æÀï »óȲ

Á¦12Àå ºÎ·Ï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Persistence Market Research has conducted a thorough analysis of the Idiopathic Thrombocytopenic Purpura Therapeutics Market, providing a comprehensive report detailing its global landscape. This in-depth publication offers valuable insights into the market's dynamics, trends, opportunities, and challenges, providing a comprehensive overview of its structure. Backed by exclusive data and statistics, the research predicts the anticipated growth trajectory of the Idiopathic Thrombocytopenic Purpura Therapeutics Market spanning from 2023 to 2030.

The Idiopathic Thrombocytopenic Purpura Therapeutics market is projected to grow steadily at a compound annual growth rate (CAGR) of 5.0%, reaching a value of US$0.92 billion by the conclusion of 2030, up from US$0.65 billion in 2023.

Key Insights:

Idiopathic Thrombocytopenic Purpura Therapeutics Market - Report Scope

Idiopathic thrombocytopenic purpura (ITP) is a rare autoimmune disorder characterized by low platelet counts, leading to increased risk of bleeding. The condition involves the immune system mistakenly attacking and destroying platelets crucial for blood clotting. Global market growth in ITP therapeutics is driven by innovative treatment options, advancements in medical research and technology, and a growing prevalence of ITP cases worldwide. Increased awareness and diagnosis rates, along with collaboration among regulatory bodies, pharmaceutical firms, and healthcare providers, are further propelling market expansion. Ongoing therapeutic developments and efforts towards personalized medicine are also contributing to market growth.

Market Growth Drivers

Increased research and development efforts are boosting the global idiopathic thrombocytopenic purpura (ITP) therapeutics market, with a focus on understanding the disorder's complexity and developing targeted treatments. Collaboration among stakeholders and advanced technologies are driving progress. However, limited awareness and underdiagnosis remain challenges, hindering timely diagnosis and treatment, as well as the execution of robust clinical trials.

Market Restraints

The significant financial strain stemming from the high costs of novel idiopathic thrombocytopenic purpura (ITP) treatments is a key factor impacting the global market. Despite their effectiveness and reduced side effects, the expense of targeted therapies and immunomodulators poses challenges to widespread adoption. This financial burden affects healthcare systems, insurers, and patients, compounded by the long-term management needs of ITP. Beyond drug costs, ongoing monitoring, supportive care, and potential interventions for bleeding episodes add to the economic burden.

Opportunities

The expanding utilization of immunomodulators and targeted therapies is driving growth in the global idiopathic thrombocytopenic purpura (ITP) therapeutics market. These therapies offer a more precise and effective approach by modulating specific immune system components responsible for platelet destruction. Innovations like monoclonal antibodies, targeting B cells and spleen tyrosine kinase, have reshaped treatment paradigms and shown promise in clinical trials. Ongoing research into novel targets, such as thrombopoietin receptor agonists, adds further optimism for the development of new therapeutic options.

Key Questions Answered in Report::

Competitive Intelligence and Business Strategy

Prominent entities in the idiopathic thrombocytopenic purpura (ITP) therapeutics market, such as Novartis AG, Rigel Pharmaceuticals, and Amgen Inc., prioritize strategic initiatives to secure optimal market share. A significant focus on research and development (R&D) allows for the introduction of innovative therapies, particularly immunomodulators and targeted treatments, aimed at addressing unmet patient needs. These companies invest heavily in marketing efforts to raise awareness among healthcare professionals and patients, enhancing product acceptance and market dominance. Strategic partnerships with academic and research institutions facilitate access to cutting-edge technologies and accelerate the development and commercialization of ITP therapeutics. Collaboration with healthcare providers and advocacy groups further strengthens understanding of patient needs and promotes tailored solutions.

Key Companies Profiled

Idiopathic Thrombocytopenic Purpura Therapeutics Market Segmentation

By Disease Type:

By Product:

By Region:

Table of Contents

1. Executive Summary

2. Market Overview

3. Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

4. Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Outlook: Region

5. North America Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

6. Europe Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

7. East Asia Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

8. South Asia & Oceania Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

9. Latin America Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

10. Middle East & Africa Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

11. Competition Landscape

12. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â